Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation-Reference-Cited by-同舟云学术

Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation

Published:2012-10-31 Issue:1 Volume:15 Page:57-68
ISSN:1523-5866
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Li Sichen,Chou Arthur P.,Chen Weidong,Chen Ruihuan,Deng Yuzhong,Phillips Heidi S.,Selfridge Julia,Zurayk Mira,Lou Jerry J.,Everson Richard G.,Wu Kuan-Chung,Faull Kym F.,Cloughesy Timothy,Liau Linda M.,Lai Albert

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/15/1/57/16855152/nos261.pdf

Reference46 articles.

1. Glioma classification: a molecular reappraisal;Louis;Am J Pathol,2001

2. The 2007 WHO classification of tumours of the central nervous system;Louis;Acta Neuropathol,2007

3. An integrated genomic analysis of human glioblastoma multiforme;Parsons;Science,2008

4. Analysis of the IDH1 codon 132 mutation in brain tumors;Balss;Acta Neuropathol,2008

5. IDH1 and IDH2 mutations in gliomas;Yan;N Engl J Med,2009

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Relationship Between the Molecular Phenotypes of Brain Gliomas and the Imaging Features and Sensitivity of Radiotherapy and Chemotherapy;Clinical Oncology;2024-09

2. The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas;Neuro-Oncology;2024-06-29

3. Increased chemosensitivity of IDH1-mutated gliomas due to impairment of RPA1-mediated DNA repair;2024-06-28

4. Brainstem Gliomas With Isocitrate Dehydrogenase Mutation: Natural History, Clinical-Radiological Features, Management Strategy, and Long-Term Outcome;Neurosurgery;2024-06-11

5. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation;Cancer Letters;2024-04